[Zafirlukast therapy of patients with mild-to-moderate bronchial asthma].
The recently compiled clinical experiences support the previous theory, that the cysteinil-leukotriens have an important role in the pathomechanism of bronchial asthma. Zafirlukast is a selective antagonist of the receptor 1 of cysteinil-leukotriens, and its use reduces the severity of asthma symptoms. The effect of 20 mg zafirlukast b.i.d was studied in 31 patients with mild-moderate asthma bronchiale. During the 6 week treatment period, even several hours after the first zafirlukast dose the pulmonary function improved significantly. This effect sustained during the whole treatment period, the patients' symptoms lessened and there was a significant reduction in the frequency of beta-2 agonist's use. No adverse events causally related to zafirlukast's use were detected. Zafirlukast is an efficient therapy of mild to moderate asthma bronchiale.